MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on June 14, 2005; DOI: 10.1124/mol.105.012187


0026-895X/05/6803-830-839$20.00
Mol Pharmacol 68:830-839, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.012187v1
68/3/830    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, J.
Right arrow Articles by Cass, C. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, J.
Right arrow Articles by Cass, C. E.

Uridine Binding and Transportability Determinants of Human Concentrative Nucleoside Transporters

Jing Zhang, Kyla M. Smith, Tracey Tackaberry, Frank Visser, Morris J. Robins, Lars P. C. Nielsen, Ireneusz Nowak, Edward Karpinski, Stephen A. Baldwin, James D. Young, and Carol E. Cass

From the Departments of Oncology (J.Z., T.T., F.V., and C.E.C.) and Physiology (K.M.S., E.K., and J.D.Y.), Membrane Protein Research Group (J.Z., K.M.S., T.T., F.V., J.D.Y. and C.E.C.), University of Alberta, and the Cross Cancer Institute (J.Z., T.T., F.V. and C.E.C.), Edmonton, Alberta, Canada; the Department of Chemistry and Biochemistry, Brigham Young University, Provo, Utah (M.J.R., L.P.C.N., and I.N.); and the School of Biochemistry and Molecular Biology, University of Leeds, Leeds, United Kingdom (S.A.B.)

Human concentrative nucleoside transporters 1, 2, and 3 (hCNT1, hCNT2, and hCNT3) exhibit different functional characteristics, and a better understanding of their permeant selectivities is critical for development of nucleoside analog drugs with optimal pharmacokinetic properties. In this study, the sensitivity of a high-throughput yeast expression system used previously for hCNT1 and hCNT3 was improved and used to characterize determinants for interaction of uridine (Urd) with hCNT2. The observed changes of binding energy between hCNT2 and different Urd analogs suggested that it interacts with C(3')-OH, C(5')-OH, and N(3)-H of Urd. The C(2') and C(5) regions of Urd played minor but significant roles for Urd-hCNT2 binding, possibly through Van der Waals interactions. Because the yeast assay only provided information about potential transportability, the permeant selectivities of recombinant hCNT1, hCNT2, and hCNT3 produced in Xenopus laevis oocytes were investigated using a two-electrode voltage clamp assay. hCNT1-mediated transport was sensitive to modifications of the N(3), C(3'), and C(5') positions of Urd. hCNT2 showed some tolerance for transporting Urd analogs with C(2') or C(5) modifications, little tolerance for N(3) modifications, and no tolerance for any modifications at C(3') or C(5') of Urd. Although hCNT3 was sensitive to C(3') modifications, it transported a broad range of variously substituted Urd analogs. The transportability profiles identified in this study, which reflected the binding profiles well, should prove useful in the development of anticancer and antiviral therapies with nucleoside drugs that are permeants of members of the hCNT protein family.


Received February 22, 2005; accepted June 14, 2005

Address correspondence to: Dr. Carol E. Cass, Department of Oncology, University of Alberta, Cross Cancer Institute, 11540 University Ave., Edmonton, Alberta, Canada T6H 1Z2. E-mail: carol.cass{at}cancerboard.ab.ca




This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
V. L. Damaraju, A. N. Elwi, C. Hunter, P. Carpenter, C. Santos, G. M. Barron, X. Sun, S. A. Baldwin, J. D. Young, J. R. Mackey, et al.
Localization of broadly selective equilibrative and concentrative nucleoside transporters, hENT1 and hCNT3, in human kidney
Am J Physiol Renal Physiol, July 1, 2007; 293(1): F200 - F211.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
I. M. Larrayoz, A. Fernandez-Nistal, A. Garces, E. Gorraitz, and M. P. Lostao
Characterization of the rat Na+/nucleoside cotransporter 2 and transport of nucleoside-derived drugs using electrophysiological methods
Am J Physiol Cell Physiol, December 1, 2006; 291(6): C1395 - C1404.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Zhang, K. M. Smith, T. Tackaberry, X. Sun, P. Carpenter, M. D. Slugoski, M. J. Robins, L. P. C. Nielsen, I. Nowak, S. A. Baldwin, et al.
Characterization of the Transport Mechanism and Permeant Binding Profile of the Uridine Permease Fui1p of Saccharomyces cerevisiae
J. Biol. Chem., September 22, 2006; 281(38): 28210 - 28221.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. L. Clarke, V. L. Damaraju, J. Zhang, D. Mowles, T. Tackaberry, T. Lang, K. M. Smith, J. D. Young, B. Tomkinson, and C. E. Cass
The Role of Human Nucleoside Transporters in Cellular Uptake of 4'-Thio-beta-D-arabinofuranosylcytosine and beta-D-Arabinosylcytosine
Mol. Pharmacol., July 1, 2006; 70(1): 303 - 310.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics